Global Companion Diagnostics Partnering Terms and Agreements 2010-2020
US$ 3,495.00
... Case studies of real-life Companion Diagnostics deals Access to Companion Diagnostics contract documents Leading Companion Diagnostics deals by value since 2014 Most active Companion Diagnostics dealmakers since 2014 In Global Companion Diagnostics Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
300 pages
Global Cancer Vaccine Partnering Terms and Agreements 2010-2020
US$ 3,495.00
... Case studies of real-life Cancer Vaccine deals Access to Cancer Vaccine contract documents Leading Cancer Vaccine deals by value since 2014 Most active Cancer Vaccine dealmakers since 2014 In Global Cancer Vaccine Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
250 pages
Global Antibody Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... announced in the healthcare sectors, covering: Antibodies Antibody-drug conjugates Monoclonal antibodies Murine mAb Chimeric mAb Humanized mAb Human aAb Polyclonal Antibodies Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process ...
November 2020
950 pages
Global Oncology Partnering 2015-2020: Deal trends, players and financials
US$ 3,495.00
... , Vomiting, Chemotherapy, Radiotherapy, Adenocarcinoma, Basal cell carcinoma, Bile duct cancer, Bladder cancer, Bone cancer, Brain cancer, Breast cancer, Cervical cancer, Colorectal cancer, Endometrial, Esophageal cancer, Gastric cancer, Head and neck cancer, Kaposi's sarcoma, Kidney cancer, Leukemia, Acute ...
November 2020
2600 pages
Global Antibiotics Partnering Terms and Agreements 2010 to 2020
US$ 3,495.00
... healthcare sectors, covering: Antibiotics Aminoglycosides Cephalosporin Clindamycin Macrolides Penicillin Quinolones Sulfonamides Tetracycline Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into ...
November 2020
250 pages
Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... Case studies of real-life Cancer Diagnostics deals Access to Cancer Diagnostics contract documents Leading Cancer Diagnostics deals by value since 2014 Most active Cancer Diagnostics dealmakers since 2014 In Global Cancer Diagnostics Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
500 pages
Global Orphan Diseases Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... to hundreds of Orphan Diseases deal contract documents Comprehensive access to over 120 Orphan Diseases deal records The leading Orphan Diseases deals by value since 2014 Most active Orphan Diseases dealmakers since 2014 In Global Orphan Diseases Partnering 2014 to 2019, available deals and ...
November 2020
200 pages
Global Diagnostics Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... healthcare sectors, covering: Companion Diagnostics Imaging CT Endoscope Molecular and nuclear MRI Ultrasound X-ray PET SPECT Angiography Fluroscopy Mammography In vitro diagnostics Molecular diagnostics Prognostics Theranostics The report provides a detailed ...
November 2020
1450 pages
Global Drug Delivery Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... Drug Delivery deals Access to Drug Delivery contract documents Leading Drug Delivery deals by value since 2014 Most active Drug Delivery dealmakers since 2014 In Global Drug Delivery Partnering 2014-2019: Deal ... at signing Deal component type Specific therapy target Technology type Each deal title links ...
November 2020
750 pages
Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... of real-life In Vitro Diagnostics deals Access to In Vitro Diagnostics contract documents Leading In Vitro Diagnostics deals by value since 2014 Most active In Vitro Diagnostics dealmakers since 2014 In Global In Vitro Diagnostics Partnering 2014-2019: Deal trends, players ...
November 2020
350 pages
Global Stem Cell Partnering Terms and Agreements 2010-2020
US$ 3,495.00
... Case studies of real-life Stem Cell deals Access to Stem Cell contract documents Leading Stem Cell deals by value since 2014 Most active Stem Cell dealmakers since 2014 In Global Stem Cell Partnering 2014-2019: Deal trends, players, financials and ...
November 2020
450 pages
Global Precision Medicine Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies DESCRIPTION The Global Precision Medicine Partnering 2014-2019 report provides comprehensive understanding ...
November 2020
700 pages
Global COVID-19 Partnering - 12 month subscription
US$ 2,495.00
SUMMARY The Global COVID-19 Partnering report provides comprehensive understanding and unprecedented access to the COVID-19 partnering deals and agreements entered into by the worlds leading healthca...
November 2020
450 pages
Global Cardiovascular Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular ...
October 2020
500 pages
Global Central Nervous System Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig ...
October 2020
950 pages
Global Dental Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... DESCRIPTION Global Dental Partnering 2014 to 2019 provides the full collection of Dental disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Dental partnering deals Financial deal terms ...
October 2020
200 pages
Global Gastrointestinal Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... , Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation ...
October 2020
300 pages
Global Dermatology Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... deals for the following indications: Acne, Actinic keratosis, Angioedema, Burns, Cellulitis, Cosmetics, Dermatitis, Diabetic foot ulcer, Eczema, Hair disorders, Alopecia, Impetigo, Itching, Nail disorders, Psoriasis, Rosacea, Scabies, Sun damage, Rash, Scar, Venous ulcer, Verruca, Wound healing, Wrinkles ...
October 2020
400 pages
Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014 to 2020
US$ 3,495.00
... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...
October 2020
450 pages
Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2020
US$ 3,495.00
... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...
October 2020
2800 pages
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2020
US$ 3,495.00
... latest licensing agreements announced in the pharmaceutical, biotechnology ... licensing deals by value since 2014 Most active licensing dealmakers since 2014 The leading licensing partnering resources In Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014- 2019 available deals ...
October 2020
2400 pages
Global Option and Evaluation Partnership Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020
US$ 3,495.00
... including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche ...
October 2020
850 pages
Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2020
US$ 3,495.00
... including the technology licensed, royalty rates, license fees, upfront and milestone payments. DESCRIPTION The Global Royalty Rate Trends in Pharma ... licensed, royalty rates, license fees, upfront and milestone payments. This report provides details of the latest partnering deals which disclose a royalty rate ...
October 2020
450 pages
Global Autoimmune Partnering 2014-2020: Deal trends, players and financials
US$ 3,495.00
... autoimmune diseases: Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma ...
October 2020
650 pages
Global Pediatrics Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... to hundreds of Pediatrics deal contract documents Comprehensive access to over 200 Pediatrics deal records The leading Pediatrics deals by value since 2014 Most active Pediatrics dealmakers since 2014 In Global Pediatrics Partnering 2014 to 2019, available deals and ...
September 2020
450 pages
Global Public Health Partnering 2010-2020: Deal trends, players and financials
US$ 3,495.00
... access to Public Health trends and structure of deals entered into by leading companies worldwide. Global Public Health Partnering 2014 to 2019 includes: Trends in Public Health dealmaking in the biopharma industry since 2014 Analysis of Public Health deal structure ...
September 2020
350 pages
Global Academic and Non-Profit Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... Academic and Non-Profit deals Access to Academic and Non-Profit contract documents Leading Academic and Non-Profit deals by value since 2014 Most active Academic and Non-Profit dealmakers since 2014 In Global Academic and Non-Profit Partnering ...
September 2020
3000 pages
Global Animal Health Partnering Terms and Agreements 2010 to 2020
US$ 3,495.00
... access to actual Animal Health contracts entered into by leading biopharma companies Identify most active Animal Health dealmakers since 2014 Insight into terms included in a Animal Health partnering agreement, with real ...
September 2020
350 pages
Global Big Pharma Partnering Terms and Agreements 2014-2020
US$ 3,495.00
... an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies including Pfizer, Sanofi, Abbott, GlaxoSmithKline, Johnson & Johnson ...
September 2020
1400 pages
Global Biotech Partnering Terms and Agreements 2016-2020
US$ 3,495.00
SUMMARY Global Biotech Partnering Terms and Agreements 2014 to 2019 report provides a detailed understanding and analysis of how and why companies enter Biotech partnering deals DESCRIPTION Global Biotech Partnering Terms and Agreements 2014 ...
September 2020
2900 pages
Global Medical Device Partnering Terms and Agreements 2014-2020
US$ 3,495.00
SUMMARY Global Medical Device Partnering Terms and Agreements 2014-2019 report provides a detailed understanding and analysis of how and why companies enter Medical Device partnering deals DESCRIPTION Global Medical Device Partnering Terms and Agreements 2014 ...
September 2020
1300 pages
